Dr. Fairooz Kabbinavar MD Medical Oncologist
Dr. Fairooz Kabbinavar is a medical oncologist in Los Angeles, California. He is affiliated with multiple hospitals in the area, including Ronald Reagan University of California Los Angeles Medical Center and Santa Monica-UCLA Medical Center and Orthopaedic Hospital. He received his medical degree from Indira Gandhi Medical College and has been in practice for 24 years. Dr. Kabbinavar accepts several types of health insurance, listed below. He is one of 35 doctors at Ronald Reagan University of California Los Angeles Medical Center and one of 21 at Santa Monica-UCLA Medical Center and Orthopaedic Hospital who specialize in Medical Oncology. He also speaks multiple languages, including Hindi/Urdu.
Are you Dr. Fairooz Kabbinavar? Claim your profile to make edits or add details. Edit Profile
Specialty & Clinical Interests
Medical Oncologist: Genitourinary, Head & Neck Cancer, Thoracic Cancer
Ronald Reagan University of California Los Angeles Medical Center
Ranked #11 in Cancer
Education & Medical Training
Beth Israel Deaconess Medical Center
Residency, Internal Medicine, 1986 - 1989
UCLA Medical Center
Fellowship, Hematology, 1991 - 1994
Indira Gandhi Medical College
Class of 1979
Certifications & Licensure
American Board of Internal Medicine
Certified 22 years in Internal Medicine
American Board of Internal Medicine
Certified 17 years in Medical Oncology
CA State Medical License
Active through 2013
MA State Medical License
Active through 2014
Publications & Presentations
Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer.
Garon, E. B.,Christofk, H. R.,Hosmer, W.,Britten, C. D.,Bahng, A.,Crabtree, M. J.,Hong, C. S.,Kamranpour, N.,Pitts, S.,Kabbinavar, F.,Patel, C.,von Euw, E.,Black, A.,Michelakis, E. D.,Dubinett, S. M.,Slamon, D. J.
ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Johnson, B. E.,Kabbinavar, F.,Fehrenbacher, L.,Hainsworth, J.,Kasubhai, S.,Kressel, B.,Lin, C. Y.,Marsland, T.,Patel, T.,Polikoff, J.,Rubin, M.,White, L.,Yang, J. C.,Bowden, C.,Miller, V.
Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.
Fishman, M. N.,Srinivas, S.,Hauke, R. J.,Amato, R. J.,Esteves, B.,Cotreau, M. M.,Strahs, A. L.,Slichenmyer, W. J.,Bhargava, P.,Kabbinavar, F. F.
- Aetna Choice POS II
- Aetna HMO
- BCBS Blue Card PPO
- BCBS California CaliforniaCare HMO
- BCBS California PPO
- BCBS Illinois Blue Advantage HMO
- BCBS Illinois BlueChoice Select
- BCBS Illinois HMO
- BCBS Illinois PPO
- CIGNA HMO
- CIGNA Open Access
- CIGNA PPO
- Coventry Health Care PPO Platinum
- Coventry Missouri - HMO/POS
- Excellus BCBS BluePPO
- Excellus BCBS HMOBlue
- First Health PPO
- GHI PPO
- Great West PPO
- Health Net California Large Group PPO
- HealthLink PPO
- HIP of New York - Select PPO
- Humana ChoiceCare Network PPO
- Multiplan PHCS PPO
- Multiplan PHCS PPO - Kaiser
- Multiplan PPO
- Pacificare HMO
- United Healthcare - Direct Choice Plus POS
- United Healthcare - Direct Options PPO
Help Us Keep the "U.S. News Doctor Finder" Current
If you are aware of information on this pagethat is out of date or incorrect, please let us know.
*Required Field | Your email will not be used for marketing.
Your Message Has Been Submitted
As part of our research on the correction you submitted, you may be contacted at the email address provided.
Sorry, Your Message Could Not Be Submitted
Please try again later, or E-mail your message to firstname.lastname@example.org and include the Web address (URL) of the page that contains incorrect information.
200 UCLA Medical Plaza
Los Angeles, CA 90095
Phone: (310) 206-3921
Fax: (310) 794-3512